VSee Health, Inc. (VSEE)
NASDAQ: VSEE · Real-Time Price · USD
0.369
-0.008 (-2.12%)
At close: Feb 27, 2026, 4:00 PM EST
0.368
-0.001 (-0.33%)
After-hours: Feb 27, 2026, 4:57 PM EST

Company Description

VSee Health, Inc. provides telehealth care solutions in the United States.

The company offers iDoc Telehealth solutions that treat and coordinate care for acutely ill patients in the neurointensive care, cardiac intensive care, and intensive care units for stroke, spinal cord, brain trauma, and other neurological conditions.

It also provides telehealth software building blocks, such as patient engagement, clinician staffing, remote physical exam and remote patient monitoring, and AI for telesitter and telenursing solutions; data connectors; and workflow templates.

The company distributes its products through third-party resellers and affiliated hospitals, as well as sales executives.

VSee Health, Inc. is headquartered in Newton, Massachusetts.

VSee Health, Inc.
VSee Health logo
Country United States
Founded 2008
Industry Health Information Services
Sector Healthcare
Employees 154
CEO M.D. Dr. Imoigele P. Aisiku M.B.A.

Contact Details

Address:
One Gateway Center, Suite 507
Newton, Massachusetts 02458
United States
Website vseehealth.com

Stock Details

Ticker Symbol VSEE
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001864531
CUSIP Number 92919Y102
ISIN Number US92919Y1029
Employer ID 86-2970927
SIC Code 8000

Key Executives

Name Position
Dr. Imoigele P. Aisiku M.B.A., M.D. Co-Chief Executive Officer and Director
Dr. Milton Chen Ph.D. Co-Chief Executive Officer and Chairman of the Board
Jerry Leonard CPA, M.B.A. Chief Financial Officer, Senior Vice President and Secretary
Erika Chuang Ph.D. Chief of Products

Latest SEC Filings

Date Type Title
Feb 23, 2026 SCHEDULE 13G/A Filing
Feb 19, 2026 8-K Current Report
Feb 17, 2026 SCHEDULE 13G Filing
Feb 17, 2026 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Feb 5, 2026 DEF 14A Other definitive proxy statements
Feb 3, 2026 SCHEDULE 13G/A Filing
Jan 26, 2026 PRE 14A Other preliminary proxy statements
Jan 8, 2026 424B3 Prospectus
Jan 7, 2026 EFFECT Notice of Effectiveness
Jan 2, 2026 8-K Current Report